Alvotech SA, a leading global biotech company, has expanded its partnership with Advanz Pharma, a UK-based pharmaceutical company, to commercialize three additional biosimilars in Europe. The agreement grants Advanz Pharma exclusive rights to market biosimilar candidates for Ilaris® (canakinumab) and Kesimpta® (ofatumumab), along with a third undisclosed biosimilar. This collaboration, which builds on previously partnered programs, underscores Advanz Pharma's commitment to enhancing access to rare disease and specialty medicines. The partnership involves development and commercial milestones worth up to US$180 million and includes a revenue-sharing model. Alvotech will handle development and supply, while Advanz Pharma will focus on registration and commercialization in Europe.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.